JWCI to take part in Ph III Dulcuth trial

The John Wayne Cancer Institute, at Saint John's Health Center in Santa Monica, California, will take part in USA-based Delcath Systems' Phase III trial for the treatment of metastatic melanoma in the liver. JWCI is the eighth center in this program wihh cis testing the company's percutaneous hepatic perfusion system for the isolated, high-dose delivery of the anticancer agent melphalan.

Delcath and JWCI have entered into a clinical research agreement to conduct the late-stage National Cancer Institute led study. Principal investigator of the trial, Mark Faries, said, "Delcath's technology is a much needed advancement for the treatment of unresectable melanomas in the liver. There has been a large body of research supporting the targeted high-dose delivery of melphalan for these cancers, and PHP holds tremendous promise for the treatment of melanoma as well as other cancers in the liver. I am very excited to be enrolling patients in this trial, and providing them with a much needed therapy for a disease that offers limited options."